New Start-Up Tempus Co-Founded By Eric Lefkofsky Reaches Unicorn Funding

0

Posted by omeditors | Posted in Cancer, Company | Posted on 07-06-2018

Eric Lefkofsky is proud of the work his new start-up, Tempus, which he cofounded, is doing. As the CEO, Lefkofsky is responsible for the direction the company is doing. Tempus, a tech firm that specializes in collecting and analyzing patient treatment data for cancer patients has already done some important work during the short period it has been in existance. Since 2015 Tempus has already partnered with the Mayo Clinic and other important cancer treatment centers to create a database that oncologists can use when deciding on treatment options for their patients. They are collecting molecular data from patients, as well as trying do discover and analyze trends in the treatment of cancer patients.

The great strides that Tempus has already made have atracted the attention of investors who have put thier faith in the start-up company. During the most recent round of funding, Tempus raised 80 million in funding bringing them over the 1 billion threshold and making them reach what is called Unicorn status. Unicorn status is when a privately owned company is valued at 1 Billion dollars or more, without going public. It is a very rare thing, like a unicorn and is considered an impressive achievement. It is incredibly impressive that Tempus was able to reach Unicorn status in such a short time.

The hard work of Eric Lefkofsky and his team are the reason why Tempus was able in attract investors such as New Enterprise Assciates and Kinship Trust Co. These investors were attracted to the strong relationship that Tempus has with doctors, clinics, and drug companies, all of whom wish to use this date to help treat patients more effiently.

Lefkofsky and Tempus have big plans for the future, and reaching unicorn status is an important part of those plans. Although the company currently employs 400 people in the Chicago area, they are rapidly growing and adding new employees. Since the latest round of funding, Tempus has been adding about 30 employees per month, and plans to continue that rate of growth for the forseeable future. This growth will help the company crunch more numbers and have the potential to help more cancer patients.

To Learn More Click Here

Write a comment